The global Sarcopenia Treatment Market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 6% during the forecast period (2022-2029).
Sarcopenia is defined by decreased muscular size, relative weakness, a lack of stamina, difficulty climbing stairs, and poor balance. The rate of muscle loss is influenced by exercise level, co-morbidities, nutrition, and others. Sarcopenia can impair one’s quality of life and cause disability. It refers to the loss of muscle mass and strength as a natural part of ageing. Sarcopenia Symptoms include decreased muscle size, weakness, loss of endurance, difficulty climbing stairs, and poor balance.
The global sarcopenia treatment market has been fueled by factors such as an increase in the elderly population and increased acceptance of vitamins and dietary supplements. Furthermore, an increase in sarcopenia cases is expected to drive the growth of the sarcopenia treatment market. Furthermore, an increase in R&D activities for the treatment of sarcopenia is expected to drive the growth of the sarcopenia treatment market.
Increasing vitamin and malnutrition deficiency in underdeveloped countries will drive market growth.
In developing and underdeveloped countries, micronutrient-rich foods are consumed in low proportions, resulting in malnutrition. The most common cause of sarcopenia is malnutrition. Malnutrition is very common in Latin America, Africa, and Southeast Asia due to poor nutritional status. As malnutrition rates rise, so does the prevalence of sarcopenia, creating a high demand for sarcopenia treatment supplements. Vitamin D and B12 deficiency are common among vegetarians and the elderly, and it is the leading cause of sarcopenia. The rising prevalence of vitamin deficiency is expected to demand sarcopenia treatment supplements.
Furthermore, according to data from World Population Prospects(WPP): 1 in 6 people in the world will be over the age of 65 (16%) by 2050, up from 1 in 11 in 2019 (9%), and 1 in 4 people in Europe and Northern America will be 65 or older by 2050. Globally, people aged 65 and up outnumbered children under five in 2018. As a result, the number of people aged 80 and over is expected to treble between 2019 and 2050, from 143 million to 426 million. As a result of the growing aging population and growing interest in preventative healthcare, supplement adoption is on the rise, a major driver in increasing demand for sarcopenia treatment.
Download Sample Brochure @ https://www.datamintelligence.com/download-sample/sarcopenia-treatment-market
By Treatment Type
- Protein Supplement
- Vitamin B12 Supplement
- Vitamin D & Calcium Supplement
By Route of Administration
To improve product penetration, the major players in the sarcopenia therapy market have been focusing on new marketing and sales techniques. In addition, the growing preference for online distribution channels has played a significant influence. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Pfizer Inc, GlaxoSmithKline Plc , Nestle SA, Sanofi SA, Bayer AG, Amway, Cadila Healthcare Ltd, Eli Lilly and Company.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the sarcopenia treatment market globally. For instance, in March 2018, BIOPHYTIS presented Sarconeos (BIO101) results for treating sarcopenia and announced patient enrolment for the SARA-INT international clinical research (ICFSR) at the 8th International Conference on Frailty & Sarcopenia Research.
Also, in July 2019, Nestle filed a patent for a high-protein blend to prevent muscle loss.
DataM Intelligence was established on an elemental idea of publishing Advanced Market Research Reports with precise data points & utmost accuracy that will accelerate the decision-making in designing disruptive solutions.